These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 33663259)
41. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Carbonaro TM; Bradstreet MP; Barrett FS; MacLean KA; Jesse R; Johnson MW; Griffiths RR J Psychopharmacol; 2016 Dec; 30(12):1268-1278. PubMed ID: 27578767 [TBL] [Abstract][Full Text] [Related]
42. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Lebedev AV; Lövdén M; Rosenthal G; Feilding A; Nutt DJ; Carhart-Harris RL Hum Brain Mapp; 2015 Aug; 36(8):3137-53. PubMed ID: 26010878 [TBL] [Abstract][Full Text] [Related]
43. Dynamic Functional Hyperconnectivity After Psilocybin Intake Is Primarily Associated With Oceanic Boundlessness. Mortaheb S; Fort LD; Mason NL; Mallaroni P; Ramaekers JG; Demertzi A Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 Jul; 9(7):681-692. PubMed ID: 38588855 [TBL] [Abstract][Full Text] [Related]
44. A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment. Burdick BV; Adinoff B Am J Drug Alcohol Abuse; 2013 Sep; 39(5):291-7. PubMed ID: 23968172 [TBL] [Abstract][Full Text] [Related]
46. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Griffiths RR; Richards WA; McCann U; Jesse R Psychopharmacology (Berl); 2006 Aug; 187(3):268-83; discussion 284-92. PubMed ID: 16826400 [TBL] [Abstract][Full Text] [Related]
47. The epistemic innocence of psychedelic states. Letheby C Conscious Cogn; 2016 Jan; 39():28-37. PubMed ID: 26675408 [TBL] [Abstract][Full Text] [Related]
48. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567 [TBL] [Abstract][Full Text] [Related]
49. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. Kometer M; Schmidt A; Jäncke L; Vollenweider FX J Neurosci; 2013 Jun; 33(25):10544-51. PubMed ID: 23785166 [TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Brown RT; Nicholas CR; Cozzi NV; Gassman MC; Cooper KM; Muller D; Thomas CD; Hetzel SJ; Henriquez KM; Ribaudo AS; Hutson PR Clin Pharmacokinet; 2017 Dec; 56(12):1543-1554. PubMed ID: 28353056 [TBL] [Abstract][Full Text] [Related]
51. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796 [TBL] [Abstract][Full Text] [Related]
52. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281 [TBL] [Abstract][Full Text] [Related]
53. An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations. Baker KM; Ulrich CM; Meghani SH Am J Hosp Palliat Care; 2023 Nov; 40(11):1261-1270. PubMed ID: 36604312 [No Abstract] [Full Text] [Related]
54. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Studerus E; Kometer M; Hasler F; Vollenweider FX J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349 [TBL] [Abstract][Full Text] [Related]
55. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667 [TBL] [Abstract][Full Text] [Related]
56. Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin/Psilocin. Dahmane E; Hutson PR; Gobburu JVS Clin Pharmacol Drug Dev; 2021 Jan; 10(1):78-85. PubMed ID: 32250059 [TBL] [Abstract][Full Text] [Related]
57. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; Weston N; Malievskaia E; Young AH J Psychopharmacol; 2022 Jan; 36(1):114-125. PubMed ID: 35090363 [TBL] [Abstract][Full Text] [Related]